▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #292 by analyst upside · 2026-06-27
CABA
Cabaletta Bio, Inc.
Healthcare · Market Cap $496M · P/E 0x
ANALYST PRICE TARGET
+340.0%
implied upside to consensus target
Current Price $3.04
Consensus Target $13.38
Bull Target $30.0
Bear Target $4.0
Analysts Covering 8
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
6
Hold
2
Sell
0
52-Week Low $1.26
52-Week High $4.23
YTD Return +37.6%
FUNDAMENTALS
Market Cap $496M
P/E Ratio (TTM) N/A
Forward P/E -2.1x
EPS (TTM) $-1.78
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.26
52-Week High $4.23
Current Price $3.04
Bear Target $4.0
Bull Target $30.0
● Now $3.04 ● Target $13.38
TRADING DATA
Avg Volume 3.8M
YTD Return +37.6%
Analyst Count 8
Consensus Buy
Upside to Target +340.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Cabaletta Bio, Inc. (CABA) is currently trading at $3.04 with a Wall Street consensus price target of $13.38, implying potential upside of 340.0% over the next 12 months. 8 analysts currently cover CABA, with a consensus rating of Buy — 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $4.0.

CABA operates in the Healthcare sector with a market capitalisation of $496M. The stock is up 37.6% year-to-date and is currently trading near the upper end of its 52-week range of $1.26 – $4.23.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OMER +361.4%
Omeros Corporation
$627M · P/E 7.6x · Underperform
PALI +414.0%
Palisade Bio, Inc.
$328M · P/E 15.8x · Buy
NAGE +268.4%
Niagen Bioscience, Inc.
$272M · P/E 16.3x · Buy
ABEO +251.4%
Abeona Therapeutics Inc.
$320M · P/E 5.9x · Buy
PLX +378.3%
Protalix BioTherapeutics, Inc.
$185M · P/E 12.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CABA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2026-05-15 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-05-04 40% win rate (10 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-03-24 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-03-24 62% win rate (8 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2025-10-31 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-10-10 31% win rate (48 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-09-05 40% win rate (10 calls)
Citigroup — Reiterated
Buy → Buy 2025-08-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →